GlassScriptPhysician profile
William H Bragdon
NPI 1346217601
$2,007.56
in general payments reported to CMS, 2019-2025
17 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $53.98 · 2021: $324 · 2022: $166 · 2023: $68.73 · 2024: $286 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $900.05 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $349.26 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $147.06 | 2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $90.66 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $75.12 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $54.18 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $42.33 | 2019-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $37.78 | 2025 | |
| Idorsia Pharmaceuticals US INC | $34.82 | 2023 | Quviviq |
| Indivior INC. | $33.53 | 2022-2023 | Perseris |
| Shionogi INC | $25.33 | 2021 | |
| Viiv Healthcare Company | $25.27 | 2021 | |
| Melinta Therapeutics, LLC | $18.63 | 2021 | |
| Bioxcel Therapeutics, INC. | $17.51 | 2023 | Igalmi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $17.36 | 2019 | |
| Seqirus USA INC | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bragdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.